Antibody-light fusion products for cancer therapeutics
Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
1. A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
(a) administering to the subject a composition comprising a tumor specific antibody linked to a fragment of a human LIGHT protein to the subject, wherein the LIGHT fragment is resistant to protease digestion and is sufficient to stimulate tumor specific cytotoxic T lymphocytes against the tumor cells;
(b) delivering a nucleic acid molecule encoding LIGHT or a fragment thereof to the primary tumor; and
(c) stimulating the tumor-specific cytotoxic T-lymphocytes against the tumor or its metastases to reduce to the growth of the primary tumor or cancer metastasis.
2. The method of claim 1 , wherein the nucleic acid molecule is delivered to a pre-existing tumor site or to a site distal to a pre-existing tumor site.
3. A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
(a) administering to the subject a pharmaceutical composition comprising a tumor-specific antibody;
(b) delivering a nucleic acid molecule encoding a LIGHT protein or a fragment thereof to the tumor, wherein the LIGHT is protease resistant;
(c) expressing the LIGHT protein or a fragment thereof stably on the surface of the tumor; and
(d) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor to reduce the growth of the tumor or cancer metastasis.
4. A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
(a) administering to the subject a pharmaceutical composition comprising a tumor-specific antibody;
(b) delivering a nucleic acid molecule encoding a protease resistant LIGHT or a fragment thereof to the primary tumor; and
(c) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor to reduce the growth of the tumor and cancer metastasis.
5. The method of claim 4 , wherein the nucleic acid is delivered to a pre-existing tumor site or at a site distal to the pre-existing tumor site.
6. The method of claim 3 , wherein the nucleic acid is delivered to a pre-existing tumor site or at a site distal to the pre-existing tumor site.
7. A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
(a) administering to the subject a composition comprising a tumor specific antibody linked to a fragment of a human LIGHT protein, wherein the LIGHT fragment is resistant to protease digestion and is sufficient to stimulate cytotoxic T lymphocytes against the tumor;
(b) delivering a nucleic acid molecule encoding a LIGHT protein or a fragment thereof to the tumor, wherein the LIGHT is protease resistant;
(c) expressing the LIGHT protein or a fragment thereof stably on the surface of the tumor; and
(d) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor or metastatic cells to reduce the growth of the tumor or cancer metastasis.
8. The method of claim 7 , wherein the nucleic acid is delivered to a pre-existing tumor site or to a site distal to the pre-existing tumor site.